This report provides an overview of neuroimmunology drug development within eight key indications across eight pharmaceutical markets.
The neuroimmune system is complex and a critical component in regulating nervous system health and disease. The publisher defines a neuroimmunology drug as an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Various neuroimmunology therapeutic strategies are being studied and used in order to help treat neurological diseases, including drugs that target different types of cytokines, drugs that bind selectively to receptors, and drugs that affect the migration of immune cells. Different types of molecules constituting neuroimmunology drugs are considered in this report including monoclonal antibodies, small molecules, recombinant products, and vaccines. This report focuses on neuroimmunology drug development within eight key indications (MS, NMOSD, GBS, CIDP, MG, AD/MCI, PD, and ALS) across eight major pharmaceutical markets (8MM: the US, 4EU, the UK, Japan, and China).
The neuroimmune system is complex and a critical component in regulating nervous system health and disease. The publisher defines a neuroimmunology drug as an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Various neuroimmunology therapeutic strategies are being studied and used in order to help treat neurological diseases, including drugs that target different types of cytokines, drugs that bind selectively to receptors, and drugs that affect the migration of immune cells. Different types of molecules constituting neuroimmunology drugs are considered in this report including monoclonal antibodies, small molecules, recombinant products, and vaccines. This report focuses on neuroimmunology drug development within eight key indications (MS, NMOSD, GBS, CIDP, MG, AD/MCI, PD, and ALS) across eight major pharmaceutical markets (8MM: the US, 4EU, the UK, Japan, and China).
Key Highlights
- Report deliverable include a PowerPoint report
- Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for MS (23 drugs), followed by three each for NMOSD and AD, and two for MG. Most marketed neuroimmunology products are small molecules (12 drugs), followed by mAbs (nine drugs) and recombinant proteins (seven drugs)
- According to the publisher's Drugs Database, there are currently almost 220 neuroimmunology drugs in Phase I, II, III, and later stages of development in the 8MM. The highest number of drugs are in development for AD (75 drugs), followed by amyotrophic lateral sclerosis (ALS) (39 drugs), PD (35 drugs), MS (26 drugs), and relapsing-remitting MS (RRMS) (26 drugs)
- The top 20 neuroimmunology products were worth $20.1 billion in 2020 and are expected to be worth $26.6 billion by 2025. Growth is driven primarily by the continued uptake of Ocrevus in MS and new launches across several indications. Extensive deal-making is occurring within the neuroimmunology drug space, with the top-valued deal being the acquisition of Alexion Pharmaceuticals by AstraZeneca, announced in December 2020
- Of the ten key players involved in the neuroimmunology market, Roche, Biogen, AstraZeneca, Johnson & Johnson (J&J), Novartis, Sanofi, and UCB are all involved in marketing or developing neuroimmunology products across multiple neurological indications. The remaining three players are instead focused on neuroimmunological products in just one indication each-Merck KGaA in MS and Eisai and Lilly in AD
Scope
- Overview of the neuroimmune system and its role in the pathology of eight key neurological diseases
- Overview of key trends in the neuroimmunology drug development space
- Evaluation of marketed and pipeline neuroimmunology drugs for the treatment of eight key neurological diseases, highlighting key mechanisms of action
- Evaluation of clinical trials for marketed and pipeline neuroimmunology drugs
- Market analysis of key neuroimmunology products in 2020 and 2025 plus an overview of key deals in the neuroimmunology space
- Overview of opportunities and unmet needs in the neuroimmunology space
- Analysis of companies developing neuroimmunology drugs, with a focus on major players
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of neuroimmunology pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global neuroimmunology drug market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuroimmunology market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Table of Contents
1. Preface1.1. Table of Contents
1.2. Abbreviations
1.3. Related Reports
2. Executive Summary
2.1. Key Findings
3. Neuroimmunology Overview
3.1. The Neuroimmune System - Overview
3.2. What Is a Neuroimmunology Drug?
3.3. CNS Autoimmune Diseases
3.3.1. Overview of multiple sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
3.4. Peripheral Nerve Autoimmune Diseases
3.4.1. Overview of Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
3.5. Neuromuscular Junction Autoimmune Diseases
3.5.1. Overview of Myasthenia Gravis (MG)
3.6. Neurodegenerative Diseases
3.6.1. Overview of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS)
4. Trends
4.1. Industry Trends
4.2. Macroeconomic Trends
4.3. Regulatory Trends
5. Value Chain
5.1. Neuroimmunology Value Chain - Autoimmune Diseases
5.2. Neuroimmunology Value Chain - Neurodegenerative Diseases
6. Marketed Drugs
6.1. Overview of Marketed Neuroimmunology Drugs
6.2. Marketed Neuroimmunology Drugs - Small Molecules
6.3. Marketed Neuroimmunology Drugs - Monoclonal Antibodies
6.4. Marketed Neuroimmunology Drugs - Recombinant Proteins
6.5. Other Marketed Neuroimmunology Drugs
7. Pipeline Products
7.1. Pipeline Neuroimmunology Overview
7.2. Pipeline Products - MS
7.2.1. Overview of Pipeline Drugs
7.2.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - MS
7.2.3. MS Pipeline Highlights: Tyrosine Protein Kinase BTK Inhibitors
7.2.4. MS Pipeline Highlights: Targeting B and T Lymphocytes
7.3. Pipeline Products - AD
7.3.1. Overview of Pipeline Drugs - AD
7.3.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - AD
7.3.3. AD Pipeline Highlights: mAbs Targeting Amyloid Beta (Aß) A4 Protein
7.3.4. AD Pipeline Highlights: Therapies Targeting Tau Protein
7.4. Pipeline Products - PD
7.4.1. Overview of Pipeline Drugs - PD
7.4.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - PD
7.4.3. PD Pipeline Highlights: a-Synuclein
7.4.4. PD Pipeline Highlights: Bcr-Abl Pathway
7.5. Pipeline Products - ALS
7.5.1. Overview of Pipeline Drugs - ALS
7.5.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - ALS
7.5.3. ALS Pipeline Highlights: Multi-target Immunomodulators
7.5.4. ALS Pipeline Highlights: Complement System
7.6. Pipeline Products - NMOSD
7.6.1. Overview of Pipeline Drugs - NMOSD
7.6.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - NMOSD
7.6.3. NMOSD Pipeline Highlights: Anti-CD20 mAbs
7.6.4. NMOSD Pipeline Highlights: Other B-cell-Targeting MOAs
7.7. Pipeline Products - MG
7.7.1. Overview of Pipeline Drugs - MG
7.7.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - MG
7.7.3. MG Pipeline Highlights: C5 Complement Inhibition
7.7.4. MG Pipeline Highlights: IgG Receptor FcRn-Blocking mAbs
7.8. Pipeline Products - GBS & CIDP
7.8.1. Overview of Pipeline Drugs - GBS & CIDP
7.8.2. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - CIDP
7.8.3. Mid-to-Late-Stage Pipeline Drugs (Phase II & III) - GBS
7.8.4. GBS & CIDP Pipeline Highlights: Complement-Targeting mAbs
7.8.5. GBS & CIDP Pipeline Highlights: IgG Autoantibody Reduction
8. Clinical Trials
8.1. Marketed Neuroimmunology Drugs - All Clinical Trials
8.2. Marketed Neuroimmunology Drugs - Ongoing or Planned Trials
8.3. Pipeline Neuroimmunology Drugs - All Clinical Trials
8.4. Pipeline Neuroimmunology Drugs - Ongoing or Planned Trials
9. Market Analysis
9.1. Top 20 Neuroimmunology Product Sales in 2020 and 2025
9.2. Top 10 M&A Deals in the Neuroimmunology Space
9.3. Top 10 Strategic Alliance Deals in the Neuroimmunology Space
10. Opportunities, Challenges, and Unmet Needs
10.1. Unmet Needs Surrounding Neuroimmunology Products - Gap Analysis
10.2. Unmet Needs - KOLs Perspective
11. Companies
11.1. F. Hoffmann-La Roche Ltd
11.2. Biogen
11.3. AstraZeneca Plc
11.4. J&J
11.5. Merck KGaA
11.6. Novartis AG
11.7. Sanofi
11.8. UCB SA
11.9. Eisai Co Ltd
11.10. Eli Lilly and Co
12. Appendix
12.1. Bibliography
12.2. Key Themes Impacting the Pharmaceutical Industry
12.3. Our thematic research methodology
12.4. About the Authors
12.5. Contact the Publisher
